The multi-factorial nature of clinical multidrug resistance in cancer
Copyright © 2019 Elsevier Ltd. All rights reserved..
Curative cancer therapy remains a major challenge particularly in cancers displaying multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a wide array of anticancer drugs harboring distinct structures and mechanisms of action. The multiple factors involved in mediating MDR may include host factors, tumor factors as well as tumor-host interactions. Among the host factors are genetic variants and drug-drug interactions. The plethora of tumor factors involves decreased drug uptake primarily via impaired influx transporters, increased drug efflux predominantly due to the overexpression of MDR efflux transporters of the ATP-binding cassette superfamily or due to drug efflux mediated by extracellular vesicles (EVs) or drug-loaded lysosomes undergoing exocytosis, deregulation of cell death mechanisms (i.e. anti-apoptotic modalities), enhanced DNA damage repair, epigenetic alterations and/or deregulation of microRNAs. The intratumor heterogeneity and dynamics, along with cancer stem cell plasticity, are important tumor factors. Among the tumor-host interactions are the role of the tumor microenvironment, selective pressure of various stressor conditions and agents, acidic pH and the intracellular transfer of traits mediated by EVs. The involvement of these diverse factors in MDR, highlights the need for precision medicine and real-time personalized treatments of individual cancer patients. In this review, written by a group of researchers from COST Action STRATAGEM "New diagnostic and therapeutic tools against multidrug resistant tumors", we aim to bring together these multidisciplinary and interdisciplinary features of MDR cancers. Importantly, it is becoming increasingly clear that deciphering the molecular mechanisms underlying anticancer drug resistance, will pave the way towards the development of novel precision medicine treatment modalities that are able to surmount distinct and well-defined mechanisms of anticancer drug resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 46(2019) vom: 15. Sept., Seite 100645 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Assaraf, Yehuda G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.03.2020 Date Revised 30.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drup.2019.100645 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301925755 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301925755 | ||
| 003 | DE-627 | ||
| 005 | 20231225105634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drup.2019.100645 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM301925755 | ||
| 035 | |a (NLM)31585396 | ||
| 035 | |a (PII)S1368-7646(19)30034-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Assaraf, Yehuda G |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The multi-factorial nature of clinical multidrug resistance in cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2020 | ||
| 500 | |a Date Revised 30.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Curative cancer therapy remains a major challenge particularly in cancers displaying multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a wide array of anticancer drugs harboring distinct structures and mechanisms of action. The multiple factors involved in mediating MDR may include host factors, tumor factors as well as tumor-host interactions. Among the host factors are genetic variants and drug-drug interactions. The plethora of tumor factors involves decreased drug uptake primarily via impaired influx transporters, increased drug efflux predominantly due to the overexpression of MDR efflux transporters of the ATP-binding cassette superfamily or due to drug efflux mediated by extracellular vesicles (EVs) or drug-loaded lysosomes undergoing exocytosis, deregulation of cell death mechanisms (i.e. anti-apoptotic modalities), enhanced DNA damage repair, epigenetic alterations and/or deregulation of microRNAs. The intratumor heterogeneity and dynamics, along with cancer stem cell plasticity, are important tumor factors. Among the tumor-host interactions are the role of the tumor microenvironment, selective pressure of various stressor conditions and agents, acidic pH and the intracellular transfer of traits mediated by EVs. The involvement of these diverse factors in MDR, highlights the need for precision medicine and real-time personalized treatments of individual cancer patients. In this review, written by a group of researchers from COST Action STRATAGEM "New diagnostic and therapeutic tools against multidrug resistant tumors", we aim to bring together these multidisciplinary and interdisciplinary features of MDR cancers. Importantly, it is becoming increasingly clear that deciphering the molecular mechanisms underlying anticancer drug resistance, will pave the way towards the development of novel precision medicine treatment modalities that are able to surmount distinct and well-defined mechanisms of anticancer drug resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acidic environment | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cancer patients | |
| 650 | 4 | |a Cell death mechanisms | |
| 650 | 4 | |a Clinical multidrug resistance | |
| 650 | 4 | |a DNA damage response and repair | |
| 650 | 4 | |a Drug compartmentalization | |
| 650 | 4 | |a Drug efflux | |
| 650 | 4 | |a Drug-drug interactions | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a Extracellular vesicles | |
| 650 | 4 | |a Genetic variants | |
| 650 | 4 | |a Intratumor heterogeneity and dynamics | |
| 650 | 4 | |a MicroRNAs | |
| 650 | 4 | |a Precision medicine | |
| 650 | 4 | |a Selection pressures | |
| 650 | 4 | |a Stem cell plasticity | |
| 650 | 4 | |a Tumor microenvironment | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Brozovic, Anamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Gonçalves, Ana Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Jurkovicova, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Linē, Aija |e verfasserin |4 aut | |
| 700 | 1 | |a Machuqueiro, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Saponara, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Sarmento-Ribeiro, Ana Bela |e verfasserin |4 aut | |
| 700 | 1 | |a Xavier, Cristina P R |e verfasserin |4 aut | |
| 700 | 1 | |a Vasconcelos, M Helena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy |d 1995 |g 46(2019) vom: 15. Sept., Seite 100645 |w (DE-627)NLM097532371 |x 1532-2084 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2019 |g day:15 |g month:09 |g pages:100645 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drup.2019.100645 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2019 |b 15 |c 09 |h 100645 | ||